Management of noncardiovascular comorbidities in patients with heart failure with reduced ejection fraction.
- Published in:
- Pharmacotherapy, 2021, v. 41, n. 6, p. 537, doi. 10.1002/phar.2528
- By:
- Publication type:
- Article
Works by Plazak, Michael E.
Results: 6
1
2
The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria.
- Published in:
- Expert Opinion on Pharmacotherapy, 2018, v. 19, n. 18, p. 2019, doi. 10.1080/14656566.2018.1538354
- By:
- Publication type:
- Article
3
Pharmacologic Management of Gout in Patients with Cardiovascular Disease and Heart Failure.
- Published in:
- American Journal of Cardiovascular Drugs, 2020, v. 20, n. 5, p. 431, doi. 10.1007/s40256-020-00400-6
- By:
- Publication type:
- Article
4
Comparison of two individualized antithrombotic protocols in HeartWare HVAD recipients.
- Published in:
- Artificial Organs, 2022, v. 46, n. 1, p. 117, doi. 10.1111/aor.14055
- By:
- Publication type:
- Article
5
Impact of high MELD scores on CMV viremia following liver transplantation.
- Published in:
- Transplant Infectious Disease, 2023, v. 25, n. 1, p. 1, doi. 10.1111/tid.14001
- By:
- Publication type:
- Article
6
An aspirin a day? Clinical utility of aspirin therapy for the primary prevention of cardiovascular disease.
- Published in:
- 2019
- By:
- Publication type:
- journal article